The Impact of GLP-1 Receptor Agonists on Physical Functioning and Quality of Life in Adults with Obesity: A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.55.70903Keywords
obesity, “GLP-1 receptor agonists”,, semaglutide, physical functioning, quality of life, narrative reviewAbstract
Background. Obesity is a chronic disease associated with impaired physical functioning and reduced quality of life. GLP-1 receptor agonists have emerged as an effective therapeutic option for weight reduction and may also provide additional benefits in these areas.
Aim. The aim of this study was to present the current state of knowledge on the effects of GLP-1 receptor agonists on physical functioning and quality of life in adults with obesity.
Material and methods. This study is a narrative literature review. The analysis was based primarily on publications identified in PubMed, as well as on full-text articles available in PubMed Central (PMC) and on publishers’ websites. Publications from 2021–2025 concerning adults with overweight or obesity were primarily included.
Results. Available evidence indicates that GLP-1 receptor agonists, particularly semaglutide, effectively reduce body weight and may also have favorable effects on physical functioning and quality of life. The most promising findings concern improvements in patient-reported physical functioning, limitations in daily activities, and weight- and health-related quality of life. Limitations of therapy include adverse effects, the possibility of weight regain after treatment discontinuation, high cost, and limited availability of these agents.
Conclusions. The evaluation of the efficacy of GLP-1 receptor agonists should not be limited solely to body weight reduction, but should also take into account the impact of therapy on physical functioning and quality of life.
References
1. Bąk-Sosnowska M, Białkowska M, Bogdański P, Chomiuk T, Dobrowolski P, et al. Clinical recommendations for the management of patients with obesity 2024: Position statement of the Polish Society for the Treatment of Obesity [in Polish]. Medycyna Praktyczna. 2024;(special issue 1):1-116.
2. Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol (Lausanne). 2021;12:706978. https://doi.org/10.3389/fendo.2021.706978
3. Dhippayom T, Meraz M, Lee H, Hur C, Inadomi JM, Veettil SK, et al. GLP-1 receptor agonists for treating obesity without diabetes: a systematic review and meta-analysis of economic evaluations. Diabetes Obes Metab. 2026;28(2):1339-1349. https://doi.org/10.1111/dom.70322
4. Wang JY, Wang QW, Yang XY, Yang W, Li DR, Jin JY, et al. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol (Lausanne). 2023;14:1085799. https://doi.org/10.3389/fendo.2023.1085799
5. Silveira EA, Mendonça CR, Delpino FM, de Souza Rosa LP, de Oliveira C, et al. Sedentary behavior, physical inactivity, abdominal obesity and obesity in adults and older adults: a systematic review and meta-analysis. Clin Nutr ESPEN. 2022;50:63-73. https://doi.org/10.1016/j.clnesp.2022.06.001
6. Curran F, Davis ME, Murphy K, Tersigni N, King A, Ngo N, et al. Correlates of physical activity and sedentary behavior in adults living with overweight and obesity: a systematic review. Obes Rev. 2023;24(11):e13615. https://doi.org/10.1111/obr.13615
7. Hamer O, Larkin D, Relph N, Dey P. Fear-related barriers to physical activity among adults with overweight and obesity: a narrative synthesis scoping review. Obes Rev. 2021;22(11):e13307. https://doi.org/10.1111/obr.13307
8. Stephenson J, Smith CM, Kearns B, Haywood A, Bissell P. The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study. BMC Public Health. 2021;21:1990. https://doi.org/10.1186/s12889-021-12009-8
9. Flølo TN, Liu HH, Andersen JR, Kolotkin RL. Exploring the relationship between obesity, weight loss and health-related quality of life: an updated systematic review of reviews. Clin Obes. 2026;16(1):e70049. https://doi.org/10.1111/cob.70049
10. Monney M, Jornayvaz FR, Gariani K. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes Metab. 2023;49(5):101470. https://doi.org/10.1016/j.diabet.2023.101470
11. Zhang J, Wei J, Lai W, Sun J, Bai Y, Cao H, et al. Focus on glucagon-like peptide-1 target: drugs approved or designed to treat obesity. Int J Mol Sci. 2025;26(4):1651. https://doi.org/10.3390/ijms26041651
12. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183
13. O’Neil PM, Rubino DM. Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. Postgrad Med. 2023;135(sup1):28-36. https://doi.org/10.1080/00325481.2022.2150006
14. Rubino D, Bjorner JB, Rathor N, Sharma AM, von Huth Smith L, Wharton S, et al. Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: patient-reported outcomes from the STEP 1-4 trials. Diabetes Obes Metab. 2024;26(7):2945-2955. https://doi.org/10.1111/dom.15620
15. Wood BS, Batchek DJ, Lynch DH, Spangler HB, Gross DC, Petersen CL, et al. Impact of EASO/ESPEN-defined sarcopenic obesity following a technology-based weight loss intervention. Calcif Tissue Int. 2024;114(1):60-73. https://doi.org/10.1007/s00223-023-01138-4
16. Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025;138(8):934-940. https://doi.org/10.1016/j.amjmed.2025.01.021
17. Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R, et al. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. 2024;11:1398059. https://doi.org/10.3389/fnut.2024.1398059
18. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. https://doi.org/10.1001/jama.2021.3224
19. Cheney C, Hunter K, Klein M. Impact of GLP-1 receptor agonists on perceived eating behaviors in response to stimuli. Diabetes Metab Syndr Obes. 2025;18:1411-1418. https://doi.org/10.2147/DMSO.S488806
20. Bliddal H, Gudbergsen H, Null NB, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. https://doi.org/10.1056/NEJMoa2403664
21. Cortes TM, Vasquez L, Serra MC, Robbins R, Stepanenko A, Brown K, et al. Effect of semaglutide on physical function, body composition, and biomarkers of aging in older adults with overweight and insulin resistance: protocol for an open-label randomized controlled trial. JMIR Res Protoc. 2024;13:e62667. https://doi.org/10.2196/62667
22. Kolotkin RL, et al. Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: patient-reported outcomes from the STEP 6 trial. Clin Obes. 2023;13(4):e12589. https://doi.org/10.1111/cob.12589
23. Bjorner JB, Larsen S, Lübker C, Holst-Hansen T. The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials. Diabetes Obes Metab. 2023;25(8):2142-2150. https://doi.org/10.1111/dom.15090
24. Gudzune KA, Stefanski A, Cao D, Mojdami D, Wang F, Ahmad N, et al. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(2):539-550. https://doi.org/10.1111/dom.16046
25. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725
26. Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis. Obes Rev. 2025;26(8):e13929. https://doi.org/10.1111/obr.13929
27. Tan HC, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. https://doi.org/10.15605/jafes.037.02.14
28. Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. https://doi.org/10.3389/fendo.2021.645563
29. Bracchiglione J, Meza N, Franco JVA, Escobar Liquitay CM, Novik AV, Ocara Vargas M, et al. Semaglutide for adults living with obesity. Cochrane Database Syst Rev. 2025;10(10):CD015092. https://doi.org/10.1002/14651858.CD015092.pub2
30. Wen J, Razick A, How-Volkman C, Bernstein E, Nadora D, Truong A, et al. An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: a literature review. Diabetes Obes Metab. 2025;27(3):1113-1122. https://doi.org/10.1111/dom.16110
31. Bae JH, Haam JH, Jeon E, Kang SY, Song S, Park CY, et al. 2024 Clinical practice guidelines for the diagnosis and pharmacologic treatment of overweight and obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr. 2025;34(4):322-343. https://doi.org/10.7570/jomes25042
32. Chu J, Zhang H, Wu Y, Huang Y, Zhu T, Zhou Z, Wang H. Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine. 2025;88:103464. https://doi.org/10.1016/j.eclinm.2025.103464
33. Codella R, Senesi P, Luzi L. GLP-1 agonists and exercise: the future of lifestyle prioritization. Front Clin Diabetes Healthc. 2025;6:1720794. https://doi.org/10.3389/fcdhc.2025.1720794
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marcela Łupina-Romaniuk, Julia Kołodziejczyk , Maria Pietrzak, Aneta Chawryło , Dominika Piecuch , Karolina Oleksińska , Gabriela Świetlicka , Paulina Pietraś , Michał Stolarczyk , Karolina Pracoń
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 107
Number of citations: 0
